Management of Heterozygous Factor V Leiden in Pregnancy Without Prior VTE

Ante‑partum Management

• Clinical surveillance alone is recommended for pregnant women who are heterozygous for Factor V Leiden, have no prior venous thrombo‑embolism (VTE) and no additional risk factors; prophylactic anticoagulation is not indicated. This is a conditional recommendation from the American Society of Hematology (ASH) based on very low‑certainty evidence. 1

• The American College of Chest Physicians (ACCP) concurs that ante‑partum clinical surveillance should be used regardless of family history of VTE. (Guideline recommendation; strength not explicitly graded). 2

• The Royal College of Obstetricians and Gynaecologists (RCOG) employs a weighted scoring system: prophylaxis throughout pregnancy is considered when the score ≥ 3, or from 28 weeks gestation when the score ≥ 2. (Guideline recommendation). 1

Post‑partum Management

• For women without a first‑degree family history of VTE, ASH recommends against routine post‑partum antithrombotic prophylaxis. Conditional recommendation, very low‑certainty evidence. 1

• If a first‑degree relative experienced VTE (especially before age 50), post‑partum prophylaxis with prophylactic‑ or intermediate‑dose low‑molecular‑weight heparin (LMWH) or vitamin‑K antagonist (target INR 2.0‑3.0) for 6 weeks is recommended over routine care. (ASH conditional recommendation; supported by ACCP). 1, 2

• When ≥ 2 additional risk factors are present (e.g., obesity, smoking, pre‑eclampsia, emergency cesarean, significant blood loss), LMWH prophylaxis for 6 weeks postpartum is advised even in the absence of family history. (ASH recommendation). 3

Choice of Anticoagulant When Prophylaxis Is Indicated

• Low‑molecular‑weight heparin (LMWH) is the preferred agent during pregnancy and the post‑partum period because it is easy to administer, carries a lower risk of adverse events, does not require routine laboratory monitoring, and is safe during breastfeeding. (Chest guideline; dosing may be prophylactic or intermediate based on clinical scenario). 2

Risk Assessment and Ongoing Monitoring

• A first‑degree family history of VTE before age 50 markedly increases post‑partum VTE risk and shifts management from surveillance to LMWH prophylaxis. (ASH and ACCP). 1, 2

• Risk factors should be reassessed at each prenatal visit; the development of new complications (e.g., pre‑eclampsia, emergency cesarean section) may trigger initiation of prophylaxis. (ASH). 3

Clinical Algorithm (Key Decision Points)

• Confirm heterozygous Factor V Leiden status and absence of prior VTE.
• Assess family history: first‑degree relative with VTE before age 50? → proceed to post‑partum LMWH for 6 weeks.
• Screen for additional risk factors (obesity, smoking, pregnancy complications) at each visit.
• Ante‑partum: clinical surveillance only unless ≥ 2 new risk factors emerge (then consider LMWH per RCOG scoring).
• Post‑partum:

Management of Factor V Leiden in Pregnant Women

Initial Evaluation and Risk Stratification

• The American Society of Hematology recommends that women with a history of venous thromboembolism (VTE) should be managed differently than those without, with consideration of prophylactic anticoagulation during pregnancy 4, 5
• A family history of VTE, especially in first-degree relatives before the age of 50, is a significant risk factor for VTE in pregnant women with Factor V Leiden 4, 5
• Previous obstetric complications, such as recurrent late fetal losses, severe pre-eclampsia, placental abruption, and intrauterine growth restriction, are associated with an increased risk of VTE in women with Factor V Leiden 6

Management During Pregnancy (Antepartum)

• For heterozygous women without a personal history of VTE, clinical surveillance alone is recommended during pregnancy, without routine prophylactic anticoagulation, according to the American Society of Hematology and the American College of Chest Physicians 4, 5
• The American College of Chest Physicians suggests that prophylactic anticoagulation should not be used to prevent a first VTE in pregnant women with Factor V Leiden, regardless of family history 5
• However, prophylactic anticoagulation should be considered in the presence of additional risk factors, such as a body mass index (BMI) ≥30 kg/m², smoking, or a history of pre-eclampsia 7

Management Postpartum

• For heterozygous women without a history of VTE, clinical surveillance alone is recommended postpartum if there are no additional risk factors 4, 5
• However, prophylactic anticoagulation is recommended postpartum if there are two or more additional risk factors, such as a BMI ≥30 kg/m², smoking, or a history of pre-eclampsia 7
• The duration of postpartum prophylaxis should be at least 10 days, and may be extended to 6 weeks if there is a family history of VTE 4, 5

Choice of Anticoagulant

• Low molecular weight heparin (LMWH) is the preferred anticoagulant during pregnancy, due to its ease of use, lower risk of adverse events, and lack of need for monitoring 7
• LMWH is safe during breastfeeding, and the recommended dose is either prophylactic or therapeutic, depending on the indication 7

Screening of Family Members

• Screening for Factor V Leiden may be offered to asymptomatic female family members, particularly those who are planning a pregnancy or using oral contraceptives 6, 8
• Women with Factor V Leiden may have an increased risk of thrombosis when using oral contraceptives, and informed consent should be obtained before screening due to potential psychosocial risks 8, 7